Healthy Volunteers
Conditions
Keywords
OMT-28, Atrial Fibrillation, SAD, MAD, First-in-Man, Cardiovascular
Brief summary
The aim of this first-in-human study is to assess the safety, tolerability, PK and exploratory pharmacodynamics (PD) of single and multiple oral ascending doses of OMT-28 in healthy male subjects to support further clinical development of OMT-28 in the indication of atrial fibrillation (AF) and to obtain data on food and gender effects of OMT-28 to guide dosing for Phase II trials.
Detailed description
This first-in-human study will be carried out in one study center involving multiple steps. Up to 100 healthy male and female subjects will be enrolled. The study consists of 4 parts: 1. a single ascending dose (SAD) part 2. a multiple ascending dose (MAD) part 3. a single dose, double cross-over food effect (FE) part. 4. a single dose gender effect part (female subjects group) The safety and PK data will be evaluated by the DSMC after each cohort to decide on further dose escalation.
Interventions
DRUGOMT-28
OMT-28 is a fully synthetic small molecule that belongs to the family of 17,18-epoxyeicosatetraenoic acids (17,18-EEQ) analogs, a natural metabolite of the omega-3 fatty acid eicosapentaenoic acid (EPA).
OTHERMatching Placebo
Microcrystalline cellulose
Sponsors
Omeicos Therapeutics GmbH
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Masking description
SAD, MAD and Gender parts: double blind randomized. Food Effect part: open label, crossover design
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. In general good physical health as determined by medical and surgical history, physical examination, 12 lead ECG, vital signs, and clinical laboratory tests 2. Normal blood pressure (Systolic Blood Pressure (SBP) between 100 to 140 mmHg (both inclusive); Diastolic Blood Pressure (DBP) ≥55, ≤89 mmHg) measured after 5 min rest in supine position. 3. SAD, MAD, and FE part: male of 18 to 45 years (inclusive) of age. 4. Gender effect part: female of 18 to 45 years (inclusive) of age.
Exclusion criteria
1. More than moderate smoker (\> 10 cigarettes/day). 2. More than moderate alcohol consumption (\> 35 g of ethanol regularly per day or \> 245 g regularly per week). 3. Use of any medication 4. One or more key safety laboratory parameters out of normal range Gender effect part Pregnant or breastfeeding women and of childbearing potential Previous assignment to treatment during this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety assessed by frequency and nature of treatment-emergent adverse events | From Day 1 to Day 21 |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetics (PK) measured by AUC0-∞ of OMT-28 in plasma in the SAD | From Day 1 to Day 21 |
| Pharmacokinetics (PK) measured by Cmax of OMT-28 in plasma in the SAD | From Day 1 to Day 21 |
| Pharmacokinetics (PK) measured by AUC0-24h of OMT-28 in plasma after single dosing in the SAD | From Day 1 to Day 28 |
| Pharmacokinetics (PK) measured by AUC0-τ after multiple dosing on Day 7 and 14 in the MAD | From Day 7 to Day 14 |
| Pharmacokinetics (PK) of OMT28 measured Cmax after multiple dosing on Day 7 and 14 in the MAD | From Day 7 to Day 14 |
| Pharmacokinetics (PK) in Food Effect and Gender Part measured by AUC0-t of OMT-28 in plasma | From Day 1 to Day 21 (Gender) and Day 28 (F&E) |
| Pharmacokinetics (PK) measured by AUC0-t of OMT-28 in plasma in the SAD | From Day 1 to Day 21 |
| Pharmacokinetics (PK) of OMT28 in Food Effect and Gender Part measured by Cmax of OMT-28 in plasma | From Day 1 to Day 21 (Gender) and Day 28 (F&E) |
| Change-from-baseline of QTcF (∆QTcF) | From baseline to Day 28 |
| Change from-baseline of heart rate | From baseline to Day 28 |
| Change from-baseline of PR interval in ECG | From baseline to Day 28 |
| Change from-baseline of QRS interval (∆HR, ∆PR and ∆QRS) | From baseline to Day 28 |
| Pharmacokinetics (PK) in Food Effect and Gender Part measured by AUC0-∞ of OMT-28 in plasma | From Day 1 to Day 21 (Gender) and Day 28 (F&E) |
Countries
Germany
Outcome results
None listed